Current Clinical Trials

  1. EMPACT-MI: A streamlined, multicenter, randomized, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with acute Myocardial Infarction
    • Patient population: high-risk patients hospitalized for acute myocardial infarction
    • Main eligibility criteria:
      • Acute myocardial infarction (type 1 - i.e, not secondary to other acute medical condition)
      • Heart failure symptoms and need for therapy
      • No history of heart failure
    • Intervention: empagliflozin 10mg daily vs placebo
  2. FINEARTS-HF: Finerenone study to investigate effectiveness and safety compared to placebo in patients with heart failure. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)
    • Patient population:  heart failure with mildly reduced or preserved  left ventricular ejection fraction (LVEF)
    • Main eligibility criteria:
      • Chronic heart failure (NYHA II-IV) and LVEF ≥40%
      • No spironolactone use
      • On diuretics
    • Intervention: finerenone vs placebo
  3. PROACTIVE-HF: A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients.
    • Patient population:  patients with heart failure
    • Main eligibility criteria:
      • Heart failure diagnosis
      • On diuretics
      • No myocardial infarction or stroke in the past 3 months
    • Intervention: Cordella™ Pulmonary Artery Sensor System
  4. PARAGLIDE-HF: A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge
    • Patient population:  patients hospitalized for acute heart failure and preserved left ventricular ejection fraction (LVEF)
    • Main eligibility criteria:
      • Acute heart failure diagnosis
      • In hospital or recently hospitalized for heart failure
      • Mildly reduced or preserved  LVEF (>40%)
    • Intervention: sacubitril-valsartan vs valsartan
  5. V-INITIATE: A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (≥70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION INITIATE).
    • Patient population: high cardiovascular risk patients
    • Main eligibility criteria:
      • Prior myocardial infarction
      • History of cardiovascular disease
      • Prior peripheral arterial disease
    • Intervention: inclisiran vs standard of care
  6. SUMMIT: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
    • Patient population: patients with heart failure and preserved ejection fraction and obesity
    • Main eligibility criteria:
      • Heart failure (NYHA class II-IV) and left ventricular ejection fraction (LVEF) ≥50%
      • Stable on medications for heart failure for 4 weeks
      • Body mass index (BMI) ≥30
    • Intervention: tirzepatide vs. placebo